Peptide Comparison
GHRP-2 vs GHRP-6
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two GHRPs in the same regimen: Moderate risk per peptide research literature. Ghrelin receptor (GHS-R1a) saturation + accelerated desensitization; may blunt long-term GH response.
Data-derived verdict
GHRP-2 has stronger documented evidence (Japan-Approved Diagnostic) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, GHRP-2 is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: cortisol; water retention. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| GHRP-2 | GHRP-6 | |
|---|---|---|
| Class | GHRP; ghrelin receptor agonist | GHRP; ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; strong GH release | GHS-R1a agonist with strong orexigenic effect |
| Route | SC / Intranasal | SC / Intranasal |
| Half-life | ~15-30 min | ~15-30 min |
| Dosage (research) | 100-300 mcg SC 1-3x daily | 100-300 mcg SC 2-3x daily |
| Evidence tier | Japan-Approved Diagnostic | Anecdotal + Animal Studies |
| Research depth | 215 indexed | 200 indexed |
| Availability | Research | Research Chemical |
| Reported risks | Cortisol/prolactin increase; hunger; water retention | Strong hunger; cortisol/prolactin rise; water retention |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHRP-2 or GHRP-6?
GHRP-2 has stronger documented evidence (Japan-Approved Diagnostic) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, GHRP-2 is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between GHRP-2 and GHRP-6?
GHRP-2 is classed as GHRP; ghrelin receptor agonist; GHRP-6 is classed as GHRP; ghrelin receptor agonist. Reported mechanism: GHRP-2, GHS-R1a agonist; strong GH release; GHRP-6, GHS-R1a agonist with strong orexigenic effect. Reported half-life: GHRP-2, ~15-30 min; GHRP-6, ~15-30 min. Routes in published studies: GHRP-2, SC / Intranasal; GHRP-6, SC / Intranasal.
Which has stronger evidence, GHRP-2 or GHRP-6?
GHRP-2 and GHRP-6 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHRP-2 is graded Japan-Approved Diagnostic, with 1 cited source on its reference page and 215 indexed studies. GHRP-6 is graded Anecdotal + Animal Studies, with 7 cited sources on its reference page and 200 indexed studies.
Which is more accessible, GHRP-2 or GHRP-6?
Neither GHRP-2 nor GHRP-6 is an FDA-approved drug. Catalog status: GHRP-2, Research; GHRP-6, Research Chemical. FDA lists GHRP-2 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023). FDA lists GHRP-6 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are GHRP-2 and GHRP-6 ever combined?
GHRP-2 and GHRP-6 appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRPs in the same regimen, moderate risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…